Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients.

Trial Profile

Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Belatacept (Primary) ; Basiliximab; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 Jul 2012 Planned number of patients changed from 250 to 275 as reported by European Clinical Trials Database.
    • 21 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 04 May 2011 Results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top